Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

NCT02903914 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT02903914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02903914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Lead sponsor
Incyte Corporation
Phase
Phase 1
Overall status
Completed
Start date
September 14, 2016
Completion date
August 15, 2022
Enrollment
260 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, colorectal cancer (crc), gastric cancer, head and neck cancer, lung cancer, mesothelioma, metastatic cancer, renal cell carcinoma (rcc), solid tumors, uc (urothelial cancer)